Hansa Biopharma

HNSA · Nasdaq Stockholm

Public Market Listing

HNSANasdaq Stockholm

Nasdaq Stockholm primary exchange listing

Live quotes, historical charts, and market capitalization for Hansa Biopharma are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Imlifidase(Idefirix)
Phase 3
Immunoglobulin G (IgG), all four human subclassesProtein / enzyme therapeutic
Chronic Kidney Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
Imlifidase · IdefirixPhase 2Kidney Transplantation in Highly Sensitized Patients
Est. primary completion 2027-02-28 · NCT05753930 · CT.gov ↗
What to watch
2030 (1)
April 2030 (1)
Imlifidase · IdefirixPhase 3Long Term Efficacy and Safety
Est. primary completion 2030-04-30 · NCT05937750 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

19 December 2026FDA action dateImlifidaseImlifidase PDUFA date
US, FDA · Hansa Biopharma · Source ↗

Recent

23 October 2026Topline resultImlifidaseIdefirix PAES study results presented at ASN Kidney Week
18 February 2026Filing acceptedImlifidaseFDA accepts imlifidase BLA
US, FDA · Hansa Biopharma · Source ↗
February 2026Filing acceptedImlifidaseFDA accepted imlifidase BLA
US, FDA · Source ↗
19 December 2025Filing submittedImlifidaseImlifidase BLA submitted
US, FDA · Hansa Biopharma · Source ↗
24 September 2025Topline resultImlifidaseConfIdeS (NCT04935177) Phase 3 met its primary endpoint
Hansa Biopharma AB · Source ↗

Financial reports

Quarterly & interim (2)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$3.8M$6.3M$71M$21Mreport ↗
View 1 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$3.2M$7.4M$27M$16Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$23M$31M$76M$54Mreport ↗

Hansa Biopharma reported full-year 2025 revenue of $22.71M, up 40.2% YoY, with R&D spend of $31.13M, down 12.4% YoY, and cash and equivalents of $76.22M. Net income or loss was not disclosed, while quarterly net burn was reported at $54.08M.

The company highlighted its December submission of a Biologics License Application to the FDA for imlifidase in highly sensitized kidney transplant patients, with Priority Review requested and a potential PDUFA date in August 2026. Initial data from the GNT-018-IDES trial showed imlifidase removed AAV antibodies without severe side effects, and the next-generation enzyme HNSA-5487 is being advanced in Guillain-Barré syndrome with FDA interactions planned for the first half of 2026. Hansa also completed a directed share issue raising 671.5 MSEK (~$71.3M).

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$16M$36M$37M$76Mreport ↗
2023-FY$13M$39M$73M$79Mreport ↗
2022-FY$15M$34M$143M$60Mreport ↗
2021-FY$4.0M$27M$98M—report ↗